- cafead   Sep 16, 2024 at 11:12: AM
via Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase 3 win for a potentially first-in-class candidate and outlining plans to seek approval.
article source
article source